Hemostasis valve plays an important role to reduce fluid loss during diagnostic and interventional procedures. These are designed to withstand higher pressure as compared to a basic Tuohy while reducing the risk of air embolism and blood loss. Rising CVD mortalities is primarily boosting the market growth. According to the World Health Organization (WHO), CVDs causes nearly 17.9 million mortalities each year, which is around 31% of all the mortalities. In addition, more than 75% of mortalities due to CVD occur in low and middle-income. Further, WHO estimates 85% of all mortalities occur due to heart attacks and strokes. This is leading to an increase in the demand for angiography and angioplasty procedures and thereby contributing towards the demand for hemostasis valve. Hemostasis valve prevents blood reflux while a catheter is placed in a vessel to perform angiography procedures. These are being significantly used in PTCA (Percutaneous transluminal coronary angioplasty) procedures. A hemostasis valve is placed at the end of the sheath, outside the body, due to which guidewires and catheters can be exchanged without blood loss. Therefore, it has significant importance for the constant irrigation of catheters and guidewires. In addition, rising focus on patient safety during interventional procedures is further encouraging the adoption of the hemostasis valves. However, FDA recalls for hemostasis valve is a major restraining factor for the growth of the market. Besides these, advances in medical devices and rising healthcare spending are offering remarkable growth opportunities for the market.

Segment Outlook

Hemostasis valve market is segmented on the basis of type and application. On the basis of type, the market is further classified into Y-connector, double Y-connector, and one-handed. On the basis of application, the market is further classified into angiography and angioplasty.

Global Hemostasis Valves Market: By Application Analysis

Among applications, angiography is expected to account for the significant share in the global hemostasis valves market. The growth in the segment is attributed to the increasing prevalence of CVDs, that in turn has led to the increasing adoption of angiography devices due to a large number of angiography procedures performed globally. Angiography is used to detect the blockage in the coronary artery and offer complete information about heart functioning and blood pressure. Therefore, it is being widely adopted procedure for early diagnosis of the condition. The procedure is performed by using specifically designed diagnostic catheters. Hemostasis valve provides access for the passage of catheters and other devices into the vessels, with no blood loss and prevents bleeding through the sheath.

Global Hemostasis Valve Market Share by Application, 2018 (%)

Source: OMR Analysis

Global Hemostasis Valves Market: By Type Analysis

Based on type, the market is further segmented into Y-connector, double Y-connector, and one-handed. Among these, the hemostasis valve Y-connectors segment is expected to contribute a significant share in the global hemostasis valves market. The segmental growth is backed by the increasing number of interventional procedures globally. Further, double Y-connector hemostasis valves market is expected to exhibit considerable growth during the forecast period.

Regional Outlook

Geographically, the global hemostasis valve market is further segmented into four major regions that include North America, Europe, Asia-Pacific, and RoW. The growth in these regions is primarily driven by rising demand for interventional procedures and improving healthcare infrastructure across countries, such as the US, China, and India. However, a lack of skilled professionals is one of the major factors restraining the growth of the market.

Global Hemostasis Valve Market Growth by Region, 2019-2025

Source: OMR Analysis

Asia-Pacific is estimated to witness lucrative growth in the market during the forecast period

Asia-Pacific is anticipated to grow significantly during the forecast period due to a significant rise in the prevalence of coronary artery disease coupled with a major shift from open to minimally invasive cardiac procedures in the region. In addition, increasing healthcare spending and focus to increase patients’ safety are surging the demand for minimally invasive angioplasty procedures in the region. These procedures are intended to open blocked arteries and restore blood flow through the artery; hence, propelling the adoption of hemostasis valve in angioplasty procedures in the region for prevention of blood loss.

Competitive Landscape

The major players in the market include Merit Medical Systems, Inc., Freudenberg Medical, LLC Boston Scientific Inc., Teleflex, Inc., Abbott Laboratories, Inc., and B. Braun Melsungen AG. The manufacturers of hemostasis valve are highly focusing on advancing their products and increasing their product portfolio with the use of crucial strategies, such as product launches, mergers and acquisitions, and geographical expansion.

Recent Developments

• In May 2019, Merit Medical Systems, Inc. declared the introduction of its Ph.D. (“Push, Hold, Deliver”) polycarbonate hemostasis control valve in the US. It is a dual-seal device with which the operators can manipulate the valve with one hand by pressing down on the cap and keep another hand free for insertion and withdrawal of interventional/diagnostic devices. It contains two seals, a primary compression seal and a secondary polyisoprene push and releases bleedback seal. This supports physicians to reduce blood loss without confining the movement of the device. The device supports for pressure injections up to 400 psi and features a clear body that offers unobstructed visibility. The device will leverage the Merit’s US offerings and advance the standard of care for procedures that use a hemostasis valve.

• In October 2017, Freudenberg Medical, LLC introduced the family of hemostasis valves, including HyperSeal and CertuSeal valves to its FlexSeal valve. These are designed to significantly improve procedural performance and hemostasis while integrated into next-generation delivery systems and catheters. These sophisticated valves can be directly incorporated into therapeutic catheter development projects in order to shorten development time, offer new design alternatives, and lower cost.

The Report Covers

• Annualized market revenues ($ million) for each market segment.
• Market value data analysis from 2018 to 2019 and forecast to 2025.
• Company share and market share data for global hemostasis valve market.
• Global corporate-level profiles of key companies operating within the global hemostasis valve market. Based on the availability of data for the category and country, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.
• Investment strategies by identifying the key market segments expected to register strong growth in the near future.
• Understand the key distribution channels and identifying the most preferred mode of product distribution.